Related Experiment Videos
[Measures for infection in multiple myeloma]
1Third Department of Internal Medicine, Kinki University School of Medicine.
Abstract:
A peculiarity of infection, as a complication of multiple myeloma in hematopoietic malignancies, is discussed. The Hanshin Study Group of Hematopoietic Disorders and Infection treated 3346 cases of bacterial infection during the past 13 years. Myeloma patients showed a low rate of 3.0% as compared with 28.2% of acute myelogenous leukemia patients. In patients with long term administration of antibiotics or bone marrow suppression, it is necessary to watch for fungus infection. Recently, new combination chemotherapy (DMVM-IFN alpha) is widely used in Japan. A high complete remission rate has been achieved by this regimen, but the incidence of infection tends to increase. Measures for infection in multiple myeloma should therefore be similar to that acute leukemia.
Insights
Infection complications in multiple myeloma patients are less common than in acute myelogenous leukemia. However, increased infection risk with new chemotherapy necessitates similar preventative measures for both conditions.
Area of Science:
- Hematology
- Infectious Diseases
- Oncology
Context:
- Multiple myeloma and acute myelogenous leukemia are hematopoietic malignancies.
- Infections are a significant complication in patients with hematologic cancers.
- The study analyzed 3346 bacterial infection cases over 13 years.
Purpose:
- To discuss the peculiarities of infection as a complication in multiple myeloma.
- To compare infection rates between multiple myeloma and acute myelogenous leukemia patients.
- To evaluate infection risks associated with new combination chemotherapy regimens.
Summary:
- Multiple myeloma patients had a lower bacterial infection rate (3.0%) compared to acute myelogenous leukemia patients (28.2%).
- Long-term antibiotic use or bone marrow suppression requires monitoring for fungal infections.
- New combination chemotherapy (DMVM-IFN alpha) shows high remission rates but increases infection incidence.
Impact:
- Highlights the need for vigilant infection monitoring in multiple myeloma, especially with advanced treatments.
- Suggests that infection management strategies for multiple myeloma should align with those for acute leukemia.
- Emphasizes the importance of proactive infection control in hematologic malignancy patients undergoing intensive therapy.